Loading...
XSHE
000710
Market cap387mUSD
Jul 10, Last price  
7.83CNY
1D
5.24%
1Q
-24.35%
Jan 2017
-83.48%
Name

Berry Genomics Co Ltd

Chart & Performance

D1W1MN
XSHE:000710 chart
P/E
—
P/S
2.98
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
-8.15%
Revenues
930m
-13.76%
286,852,054408,956,180464,161,241409,661,686331,077,628262,234,824334,164,169445,878,398921,704,9001,171,191,3401,439,789,0441,617,641,3001,540,385,7321,422,180,9211,422,180,9201,368,007,2111,368,007,2111,151,416,7841,078,165,273929,818,022
Net income
-197m
L+2.29%
2,818,75210,453,3308,076,488500,761392,987-6,156,85346,397,08243,793,181151,021,796232,749,593268,091,954390,618,304210,665,1940-110,818,5600-248,927,598-427,196,499-192,428,493-196,838,894
CFO
71m
-19.74%
11,677,9754,703,24857,755,051076,193,688048,265,43215,627,95518,909,9200074,350,103165,331,569123,056,710161,310,07594,031,45221,178,809111,006,91387,969,92170,607,732
Dividend
May 25, 20010.1413 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. The company was founded in 2010 and is headquartered in Beijing, China.
URL
https://www.berrygenomics.com/
IPO date
Apr 22, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT